BRPI0713333A2 - Potencializador de terapia de radiação - Google Patents

Potencializador de terapia de radiação Download PDF

Info

Publication number
BRPI0713333A2
BRPI0713333A2 BRPI0713333-2A BRPI0713333A BRPI0713333A2 BR PI0713333 A2 BRPI0713333 A2 BR PI0713333A2 BR PI0713333 A BRPI0713333 A BR PI0713333A BR PI0713333 A2 BRPI0713333 A2 BR PI0713333A2
Authority
BR
Brazil
Prior art keywords
group
radiation therapy
lower alkyl
potentializer
alkyl group
Prior art date
Application number
BRPI0713333-2A
Other languages
English (en)
Inventor
Fukushima Masakazu
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of BRPI0713333A2 publication Critical patent/BRPI0713333A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

POTENCIALIZADOR DE TERAPIA DE RADIAÇçO Para prover um potencializador de terapia de radiação, que, quando empregado em combinação com terapia de radiação de câncer, pode reduzir a dose de radiação e pode suavizar efeitos adversos. A invenção provê um potencializador de terapia de radiação contendo, como um ingrediente eficaz, um derivativo de uracil representado pela fórmula (1) (em que R^ 1^ representa um átomo de halogênio ou um grupo ciano; e R^ 2^ representa um grupo heterocíclico de 4 a 8 membros tendo de 1 a 3 átomos de nitrogênio e tendo opcionalmente como um substituinte um grupo alquila inferior, um grupo imíno, um grupo hidroxila, um grupo hidroximetila, um grupo metanossulfoniláxi, ou um grupo amino; um grupo amidinotio em que um átomo de hidrogênio preso a um átomo de nitrogênio pode ser substituído por um grupo alquila inferior; um grupo guanidino em que um átomo de hidrogênio preso a um átomo de nitrogênio pode ser substituído por um grupo alquila inferior ou um grupo ciano; um grupo alquilamidino inferior; ou um grupo 1-pirrolidinilmetila) ou um sal farmaceuticamente aceitável do mesmo.
BRPI0713333-2A 2006-06-30 2007-06-28 Potencializador de terapia de radiação BRPI0713333A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006181945 2006-06-30
JP2006-181945 2006-06-30
PCT/JP2007/000711 WO2008001502A1 (fr) 2006-06-30 2007-06-28 Potentialisateur de radiothérapie

Publications (1)

Publication Number Publication Date
BRPI0713333A2 true BRPI0713333A2 (pt) 2012-03-06

Family

ID=38845277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713333-2A BRPI0713333A2 (pt) 2006-06-30 2007-06-28 Potencializador de terapia de radiação

Country Status (13)

Country Link
US (2) US8148381B2 (pt)
EP (1) EP2036903B1 (pt)
JP (1) JP4852605B2 (pt)
KR (1) KR101401220B1 (pt)
CN (1) CN101484443B (pt)
AU (1) AU2007264665B2 (pt)
BR (1) BRPI0713333A2 (pt)
CA (1) CA2652811C (pt)
ES (1) ES2385850T3 (pt)
HK (1) HK1130481A1 (pt)
RU (1) RU2435587C2 (pt)
TW (1) TWI426909B (pt)
WO (1) WO2008001502A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924950B1 (fr) 2007-12-17 2012-02-24 Inst Francais Du Petrole Plateau filtrant de predistribution avec tube deverseur pour reacteur a lit fixe a co-courant descendant de gaz et de liquide
WO2013054788A1 (ja) * 2011-10-14 2013-04-18 住友重機械工業株式会社 荷電粒子線照射システム及び荷電粒子線照射計画方法
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
US9305310B2 (en) * 2012-03-19 2016-04-05 Uber Technologies, Inc. Enabling a user to verify a price change for an on-demand service
KR101928618B1 (ko) 2013-05-17 2018-12-12 다이호야쿠힌고교 가부시키가이샤 Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
CA2914999C (en) * 2013-06-17 2018-03-20 Taiho Pharmaceutical Co., Ltd. Stable crystal form of tipiracil hydrochloride and crystallization method for the same
US11654157B2 (en) 2017-01-09 2023-05-23 Shuttle Pharmaceuticals, Inc. Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
US10556872B2 (en) 2017-03-17 2020-02-11 Hampton University Fatty acid synthase inhibitors and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0763529T3 (da) 1995-03-29 2003-11-10 Taiho Pharmaceutical Co Ltd Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme
US6255314B1 (en) 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP4049477B2 (ja) * 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤
JP4110347B2 (ja) 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤

Also Published As

Publication number Publication date
EP2036903A1 (en) 2009-03-18
CN101484443A (zh) 2009-07-15
CA2652811A1 (en) 2008-01-03
AU2007264665B2 (en) 2012-06-14
RU2435587C2 (ru) 2011-12-10
TWI426909B (zh) 2014-02-21
TW200810758A (en) 2008-03-01
RU2009102974A (ru) 2010-08-10
WO2008001502A1 (fr) 2008-01-03
US20090286755A1 (en) 2009-11-19
JPWO2008001502A1 (ja) 2009-11-26
CA2652811C (en) 2014-12-09
US20120010165A1 (en) 2012-01-12
KR20090025247A (ko) 2009-03-10
JP4852605B2 (ja) 2012-01-11
ES2385850T3 (es) 2012-08-01
US8148381B2 (en) 2012-04-03
CN101484443B (zh) 2012-11-21
US8440675B2 (en) 2013-05-14
HK1130481A1 (en) 2009-12-31
EP2036903B1 (en) 2012-05-23
EP2036903A4 (en) 2010-08-25
KR101401220B1 (ko) 2014-05-28
AU2007264665A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
BRPI0713333A2 (pt) Potencializador de terapia de radiação
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
CY1115533T1 (el) Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
SG170739A1 (en) Iap bir domain binding compounds
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
UA102336C2 (uk) N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2021006274A (es) Derivados cíclicos de panteteína y usos de los mismos.
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TW200607805A (en) Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]